Journal of Postgraduate Medicine
 Open access journal indexed with Index Medicus & EMBASE  
     Home | Subscribe | Feedback  

[Download PDF
Year : 2003  |  Volume : 49  |  Issue : 1  |  Page : 55-60  

Recent advances in the diagnosis of leishmaniasis.

S Singh, R Sivakumar 
 Division of Clinical Microbiology, All India Institute of Medical Sciences, New Delhi-110 029, India. , India

Correspondence Address:
S Singh
Division of Clinical Microbiology, All India Institute of Medical Sciences, New Delhi-110 029, India.


Leishmaniasis is a parasitic disease caused by a haemoflagellate Leishmania. There are more than 21 species causing human infection. The infection is transmitted to humans through the bites of female sandflies belonging to 30 species. The disease manifests mainly in 3 forms: the visceral, the cutaneous and the mucocutaneous leishmaniasis. The diagnosis of visceral form is conventionally made by the demonstration of amastigotes of the parasite in the aspirated fluid from the bone marrow, the spleen, and rarely from the lymph nodes, or the liver. The parasite demonstration and isolation rates are rather poor from cutaneous and mucocutaneous lesions due to low parasite load and high rate of culture contamination. Recently several recombinant proteins have been developed to accomplish accurate diagnosis. Recombinant kinesin protein of 39 kDa called rK 39 is the most promising of these molecules. The antigen used in various test formats has been proved highly sensitive and specific for visceral leishmaniasis. It is useful in the diagnosis of HIV-Leishmania co-infection and as a prognostic marker. Molecular techniques targeting various genes of the parasite have also been reported, the PCR being the most common molecular technique successfully used for diagnosis and for differentiation of species.

How to cite this article:
Singh S, Sivakumar R. Recent advances in the diagnosis of leishmaniasis. J Postgrad Med 2003;49:55-60

How to cite this URL:
Singh S, Sivakumar R. Recent advances in the diagnosis of leishmaniasis. J Postgrad Med [serial online] 2003 [cited 2019 Nov 12 ];49:55-60
Available from:

Full Text

Leishmaniasis is a vector borne parasitic disease caused by a haemoflagellate, Leishmania spp. transmitted by the bite of infected phlebotomine sandfly. Depending on the causative species, it can manifest as Cutaneous Leishmaniasis (CL), Mucocutaneous Leishmaniasis (MCL), Diffused Cutaneous Leishmaniasis (DCL) or Visceral Leishmaniasis (VL). Leishmaniasis is prevalent in at least 88 countries. More than 90 percent of the cutaneous cases occur in Afghanistan, Saudi Arabia, Algeria, Brazil, Iran, Iraq, Syria and Sudan; while more than 90 percent of visceral cases occur in India and Sudan. Mucocutaneous form is mostly found in Latin America.[1],[2] Approximately 350 million people live in the area of active parasite transmission. Though several animal reservoirs have been identified in different countries for leishmaniasis, no animal reservoir of the parasite has yet been identified in India. It is presumed that skin lesions of a late sequel of the visceral form called post-kala-azar-dermal leishmanisis (PKDL) act as reservoirs.[1],[2]

The clinical and epidemiological findings in various forms of leishmaniases are non pathognomonic and these can mimick several other conditions. Hence a laboratory diagnosis is required to confirm the clinical suspicion. The diagnostic tools used for each leishmanial syndrome viz. visceral, cutaneous, and mucocutaneous form vary but the gold standard in each case remains to be the demonstration and isolation of the parasite from appropriate tissues.

  ::   Parasitological diagnosisTop

The differential diagnosis for VL includes, among others, malaria, tropical splenomegaly syndrome schistosomiasis, cirrhosis with portal hypertension, African trypanosomiasis, milliary tuberculosis, brucellosis, typhoid fever, bacterial endocarditis, histoplasmosis, malnutrition, lymphoma, and leukaemia. Similarly numerous primary and secondary skin diseases and conditions are frequently misdiagnosed as early lesions of cutaneous leishmaniasis. Some of the common conditions that should be differentiated from cutaneous leishmaniasis are tropical ulcers due to other causes, impetigo, infected insect bites, leprosy, lupus vulgaris, yaws, blastomycosis, and skin cancer.[1],[2] Mucocutaneous leishmaniasis is sequelae of new world cutaneous leishmaniasis and results from direct extension or hematogenous or lymphatic metastasis to the nasal or oral mucosa. Paracoccidioidomycosis, polymorphic reticulosis, Wegener’s granulomatosis, lymphoma, histoplasmosis, yaws, tuberculosis, nasopharyngeal carcinoma, and other destructive lesions are frequently misdiagnosed as early lesions of mucocutaneous leishmaniasis.[1],[2],[3] Hence other diagnostic methods are required to confirm the clinical suspicion.[1],[4]

The diagnosis of leishmaniasis is reliably made by the demonstration of the parasite in smears and by isolation, either in culture or by animal inoculation of a biopsy sample or tissue aspirate from the spleen, or the bone marrow. The sensitivity is highest for splenic aspiration (as high as 98%) but so is the risk of complications such as haemorrhage. Occasionally the amastigotes have also been demonstrated in liver biopsy (50-85% sensitive), lymph node aspirates and buffy coat smears, particularly in HIV-Leishmania co-infection cases.[1],[2],[3],[4] The details are shown in [Table:1].

The parasitological diagnosis of CL is made by demonstration of amastigotes in skin lesions on skin biopsy and on culture of these specimens.[1],[2] Many other methods for demonstration of parasites such as histochemical and immunohistochemical examination of smears have been described.[6],[7] Culture based diagnosis of mucocutaneous leishmaniasis has very low sensitivity as the organisms are often scant.[7] The individual sensitivities for the methods for patients and Montenegro-positive healthy controls were: histopathology: 14% and 16%; impression smear: 19% and 21%; dermal scraping: 22% and 26%; aspirate-culture: 58% and 64%; aspirate-hamster: 38% and 41%; biopsy-culture: 50% and 55%; and biopsy-hamster 52% and 57%, respectively. The sensitivity is slightly better for younger lesions than for lesions older than 6 months.[8]

Primary isolation of L. donovani is made on solid Novy- MacNeal- Nicolle (NNN) medium having 20-30% rabbit blood or liquid Schneider’s insect medium supplemented with 10% v/v foetal calf serum (FCS). Other suitable growth media can also be used, particularly for maintaining the subcultures of the promastigotes using FCS or other supplements including human urine.[5]

  ::   Serological diagnosisTop

The biggest problem with conventional smear or culture techniques is low sensitivity particularly in detecting the occult and sub-clinical infections. These techniques are also cumbersome, and time consuming, and not suitable for field. The serological diagnosis is based on the presence of specific humoral response, as in cases of visceral leishmaniasis or cell mediated immune response, as in cases of cutaneous and mucocutaneous leishmaniasis.[1] A wide range of serological methods varying in sensitivity and specificity are available for the diagnosis of VL. These serological methods can be grouped into non-specific and specific tests.

The non-specific tests had been in use in the past but are very rarely used these days. A positive test does not confirm the diagnosis of Leishmaniasis.[1] Indirect haemagglutination (IHA), counter-current immunoelectrophoresis (CCIEP), and Immunodiffusion (ID) are examples of non-specific tests. These tests are cumbersome and have lower sensitivity and specificity and hence not commonly used.[8],[9],[10] Some more commonly used ones are described below.

Leishmanin Skin Test (LST)

Delayed hypersensitivity is an important feature of cutaneous forms of human leishmaniasis and can be measured by the leishmanin test, also known as the Montenegro reaction. Leishmanin is a killed suspension of whole (0.5-1 x 10[7]/ml) or disrupted (250 µg protein/ml) promastigotes in pyrogen-free phenol saline. No cross-reactions occur with Chagas’ disease, but some cross-reactions are found with cases of glandular tuberculosis and lepromatous leprosy. Leishmanin Skin Test is usually used as an indicator of the prevalence of cutaneous and mucocutaneous Leishmaniasis in human and animal populations and successful cure of visceral leishmaniasis.[9],[11],[12] During active kala-azar disease there will be no or negligible cell mediated immune response. However, the leishmanin antigen is not commercially available and no field study has been carried out in India.

Indirect Fluorescent Antibody Test (IFAT)

The Indirect fluorescent antibody test is one of the most sensitive tests available. The test is based on detecting antibodies, which are demonstrated in the very early stages of infection and are undetectable six to nine months after cure. If the antibodies persist in low titers, it is good indication of a probable relapse. Titers above 1:20 are significant and above 1:128 are diagnostic.[5] There is a possibility of a cross reaction with trypanosomal sera. However, this can be overcome by using leishmania amastigotes as the antigen instead of the promastigotes.[10] Although this test is more sensitive (96%) and specific (98%) than soluble antigen ELISA, it is cumbersome and not suitable for field conditions.[13]

Direct Agglutination Test

The direct agglutination test (DAT) is a highly specific and sensitive test. It is inexpensive and simple to perform making it ideal for both field and laboratory use. The method uses whole, stained promastigotes either as a suspension or in a freeze-dried form. The freeze-dried form is heat stable and facilitates the use of DAT in the field. However, the major disadvantage of DAT is the relative long incubation time of 18 h and the need for serial dilutions of serum.[14],[15] Also, DAT has no prognostic value. The test may remain positive for several years after cure. Recently, Schoone et al[15] have developed a fast agglutination-screening test (FAST) for the rapid detection (<3 hours) of anti-leishmania antibodies in serum samples and on blood collected on filter paper. The FAST utilises only one serum dilution leading to qualitative results. It offers the advantages of DAT based on the freeze-dried antigen, of the antigen, reproducibility, specificity and sensitivity. Direct agglutination test has been evaluated for the diagnosis of cutaneous leishmaniasis using L. major promastigotes and was shown to be highly specific and sensitive (90.5%).[16]

Enzyme Linked Immunosorbent Assay

The Enzyme Linked Immunosorbent Assay (ELISA) is a valuable tool in the serodiagnosis of leishmaniasis. The test is useful for laboratory analysis as well as for field applications. However, the sensitivity and specificity of ELISA is greatly influenced by the antigen used [Table:2]. More recently, several recombinant antigens like rGBP from L. donovani, rORFF from L. infantum, rgp63, rK9, rK26 and rK39 from L.chagasi [17],[18],[19],[20],[21],[22] have been developed and tested. Of these, the rK39 antigen is found to be highly sensitive and predictive of onset of disease manifestation in VL patients. In contrast, it does not show detectable antibodies in cutaneous or mucocutaneous leishmaniasis. The antibody titres to this antigen directly correlate with active disease and have potential in monitoring the chemotherapy and in predicting the clinical relapse. In addition rK39 ELISA has a high predictive value for detecting VL in immunocompromised persons, like those with AIDS. A kit (InBios®, USA) using this antigen and based on lateral flow is now commercially available in the form of antigen-impregnated nitrocellulose paper strips adapted for use under field conditions. The rK39 strip test has been found highly sensitive and a reliable indicator of kala-azar in India.[23],[24],[25],[26]

Due to lack of facilities and expertise to perform skin biopsy, smears and cultures the proper diagnosis of cutaneous leishmaniasis remains under reported. The use of serological tools in the diagnosis of CL has also been assessed by a number of studies. ELISA using few recombinant antigens viz., gene B protein (GBP) from Leishmania major, recombinant major surface glycoprotein, gp63, from L. major, and 2 recombinant proteins, T26-U2 and T26-U4, from Leishmania (Viannia) peruviana have been tried but have been found less suitable for diagnosing CL.[16],[27] Laboratory diagnosis of MCL has also taken a back seat and most of the cases are diagnosed (and obviously may be over-diagnosed) clinically. [Table:2] shows comparative sensitivity and specificity of various ELISA based antibody detection techniques.[28]


Most of the work concerning the use of immunoblotting in the diagnosis of leishmaniasis has been done on visceral leishmaniasis (VL). In cutaneous leishmaniasis, anti-leishmania antibodies though detectable, are present in low tibres. Hence Immunoblotting is not widely adopted for diagnosing CL. The biggest advantage of immunoblotting, as a general rule, is that various antigens expressed and antibodies recognised during the course of infection can be documented. It also has an added advantage of permanent documentation. However, the technique is not user-friendly and limited only to research laboratories.[1],[10],[29],[30]

Antigen Detection

The antigen detection is an ideal method of diagnosing an infection. Antigen levels are expected to broadly correlate with the parasite load as well. This method of diagnosis should be a better alternative to the antibody detection methods, particularly in the immunocompromised patients, where antibody response is very poor. However, detection of antigen in the patient’s serum is complicated by the presence of high level of antibodies, circulating immune complexes, serum amyloid, rheumatoid factor and autoantibodies; all of which may mask immunologically important antigenic determinants or competitively inhibit the binding of free antigen. Though a few reports are published, no satisfactory antigen detection system is currently available.[31] Recently, a latex agglutination test (KATEX) for the detection of leishmanial antigens in the urine of patients with VL is developed.[32] The results obtained with KATEX using samples collected from patients of different foci of VL indicate that, the test works well regardless of the geographical origin of samples. The test had 100% specificity and sensitivity between 68-100%. Whether the test has applications for the detection of asymptomatic cases of VL and monitoring therapy is yet to be confirmed. There are no antigen detection systems currently available for CL and MCL.

  ::   Molecular methodsTop

Microscopy and culture have the limitations of low sensitivity and are time consuming. The immunological methods fail to distinguish between past and present infections and are not very reliable in immunocompromised patients. While the molecular approach is capable of detecting nucleic acids unique to the parasite, it would address these limitations. A variety of nucleic acid detection methods targeting both DNA and RNA have been developed. Amongst these, the PCR has proved to be a highly sensitive and specific technique. The PCR assay can detect parasite DNA or RNA a few weeks ahead of appearance of any clinical signs or symptoms. Different DNA sequences in the genome of leishmania like ITS region, gp63 locus, telomeric sequences, sequence targets in rRNA genes such as 18s rRNA and SSU-rRNA and both conserved and variable regions in kinetoplast DNA (kDNA) minicircles are being used by various workers. [33],[34],[35],[36],[37]

The PCR-SSCP technique has been developed for the detection of sequence variation in rRNA genes within the L. donovani species. In addition, it can be performed easily and rapidly from clinical samples without prior need of cultivation of the parasite. PCR assay has also been used for post therapeutic follow-up and for detection of relapses among HIV-infected patients using SSU rRNA gene target. The use of fluorogenic real-time PCR using SSU-rRNA gene added with complete automation has made quantification of parasite burden possible. Besides it is a rapid, sensitive and highly specific test.[32],[33],[34],[35],[36]

Recently, primers developed by us (unpublished data) could differentiate the Indian strains causing VL and PKDL forms. An Alu-PCR-like amplification was performed from the cultured L. donovani isolates from VL and PKDL patients. The banding pattern of the PCR amplicons could clearly group all the PKDL strains in one group while VL strains had intra-species heterogeneity as reported by us earlier.[38]

The chronic CL patients constitute the greatest diagnostic challenge due to the low density of Leishmania parasites. For acute CL, dermal scrapings from the bottom of the ulcer may yield viable specimens for PCR. Recently, the sampling method has been further improved using cotton swab for diagnosis of CL. Collection of the exudative material is easy, painless and convenient for both the patients as well as the collectors compared with other sampling methods. The collection of exudates by cotton swab may be a better alternative to biopsy samples for the diagnosis of CL by PCR, especially in field conditions.[39],[40],[41],[42]

A PCR-ELISA technique developed recently is reported to be sufficiently sensitive and specific for use as a diagnostic test in cases of mucocutaneous leishmaniasis. Using this technique, the percentage of detection was 83.3% in blood samples from clinically diagnosed cases. No false positive results were obtained.[43] However, the use of PCR as a routine diagnostic method still requires a well-prepared laboratory and well-trained personnel. This hampers the feasibility of using this technique directly in the field.

  ::   Other surrogate markersTop

There are a few surrogate markers that can be used in predicting the prognosis of the kala-azar. Besides increase in haemoglobin and total and albumin fraction of the serum protein there is consequent decrease in serum globulin after sucessful treatment. This also increases the albumin/globulin ratio. Other laboratory parameters include increase in total WBC count, and decrease in ESR and serum levels of liver enzymes. The cytokines particularly, the TNF-alpha is another such prognostic marker. This cytokine is significantly raised in acute persistent cases of kala-azar but the levels come down sharply after parasitological cure.[10]

  ::   Leishmaniasis in hiv infected patientsTop

HIV modifies the clinical presentation of leishmaniasis in the co-infected patient. Several atypical etiologic agents have been described in leishmanial syndromes affecting HIV-infected subjects. HIV-associated leishmaniasis is characterized by parasite dissemination to the skin (as in DCL), spread of the “non-visceralizing” species throughout the reticulo-endothelial system and spread to the atypical locations, as well. A review of current literature found that 20-40% cases had absence of splenomegaly. Lack of anti-Leishmania antibodies is a characteristic feature seen in these patients. Leishmania amastigotes are commonly found in Kaposi’s sarcoma and herpes zoster cutaneous lesions when HIV infected patients develope VL. Leishmaniasis has also been reported presenting with a dermatomyositis-like eruption in three patients with AIDS.[44] Though India has less experience of HIV-Leishmania co-infection the number of such cases is bound to increase in Bihar. We have seen about 10 cases at this institute. All were referred from Bihar or Uttaranchal. Usually the promastigotes can easily be seen in these patients due to heavy load of parasites. We have found high utility of anti-rK39 in these patients.


1Herwaldt BL. Leishmaniasis. Lancet. 1999;354:1191-9.
2Georgraphical Distribution of Leishmaniasis:
3El-Hassan A M, Zijlstra EE. Leishmaniasis in Sudan. Mucosal leishmaniasis.V Trans R Soc Trop Med Hyg 2001;95(Suppl 1):
5Davidson RN. Practical guide for the treatment of leishmaniasis. Drugs 1998;56:1009-18.
6Singh S, Mohapatra DP, Sivakumar R. Successful replacement of foetal calf serum with human urine for in vitro culture of Leishmania donovani. J Commun Dis 2000;32:289-94.
7Palma G, Gutierrez Y. Laboratory diagnosis of Leishmania. Clin Lab Med 1991;11:909-22.
8Rosbotham JL, Corbett EL, Grant HR, Hay RJ, Bryceson AD. Imported mucocutaneous leishmaniasis. Clin Exp Dermatol 1996;21:288-90.
9Weigle KA, de Davalos M, Heredia P, Molineros R, Saravia NG, D’Alessandro A. Diagnosis of cutaneous and mucocutaneous leishmaniasis in Colombia: a comparison of seven methods. Am J Trop Med Hyg 1987;36:489-96.
10Williams, Leishmania JE, Trypanosoma. In medical parasitology. A practical approach. In Gillespie, S H, Hawkey P M, (Eds). London: Oxford University Press; 1995.
11Singh S. Diagnostic and Prognostic markers of anti-kala-azar therapy and vaccination. Proceeding of V Round Table Conference Series. No. 5. Gupta S and Sood OP (Eds). New Delhi: Ranbaxy Science Foundation; 1999. pp. 95-114.
12Manson-Bahr PEC. Diagnosis: The Leishmaniases in Biology and Medicine, vol 2, Clinical Aspects and Control. W Peters and R Killick-Kendrick (eds). New York: Academic Press Inc; 1987. pp. 709-29.
13Sassi A, Louzir H, Ben SA, Mokni M, Ben OA, Dellagi K. Leishmanin skin test lymphoproliferative responses and cytokine production after symptomatic or asymptomatic Leishmania major infection in Tunisia.Clin Exp Immunol. 1999;116:127-32
14Gari-Toussaint M, Lelievre A, Marty P, Le-Fichoux Y. Contribution of serological tests to the diagnosis of visceral leishmaniasis in patients infected with the human immunodeficiency virus. Trans R Soc Trop Med Hyg 1994;88:301-2
15Schallig HD, Schoone GJ, Kroon CC, Hailu A, Chappuis F, Veeken H. Development and application of ‘simple’ diagnostic tools for visceral leishmaniasis. Med Microbiol Immunol (Berl). 2001;190:69-71.
16Schoone GJ, Hailu A, Kroon CC, Nieuwenhuys JL, Schallig HD, Oskam L. A fast agglutination-screening test (FAST) for the detection of anti-Leishmania antibodies. Trans R Soc Trop Med Hyg 2001;95:400-1.
17Montoya Y, Leon C, Talledo M, Nolasco O, Padilla C, Munoz-Najar U, et al. Recombinant antigens for specific and sensitive serodiagnosis of Latin American tegumentary leishmaniasis. Trans R Soc Trop Med Hyg 1997;91:674-6.
18Martin SK, Thuita-Harun L, Adoyo-Adoyo M, Wasunna KM. A diagnostic ELISA for visceral leishmaniasis, based on antigen from media conditioned by Leishmania donovani promastigotes. Ann Trop Med Parasitol 1998;92:571-7.
19Jensen AT, Gasim S, Moller T, Ismail A, Gaafar A, Kemp M. el Hassan AM, et al. Serodiagnosis of Leishmania donovani infections: assessment of enzyme-linked immunosorbent assays using recombinant L. donovani gene B protein (GBP) and a peptide sequence of L. donovani GBP. Trans R Soc Trop Med Hyg 1999;93:157-60.
20Rajasekariah GH, Ryan JR, Hillier SR, Yi LP, Stiteler JM, Cui L, et al. Optimisation of an ELISA for the serodiagnosis of visceral leishmaniasis using in vitro derived promastigote antigens. J Immunol Methods 2001;252:105-19.
21Raj VS, Ghosh A, Dole VS, Madhubala R, Myler PJ, Stuart KD. Serodiagnosis of leishmaniasis with recombinant ORFF antigen. Am J Trop Med Hyg 1999;61:482-7.
22Bhatia A, Daifalla NS, Jen S, Badaro R, Reed SG, Skeiky YA. Cloning, characterization and serological evaluation of K9 and K26: two related hydrophilic antigens of Leishmania chagasi. Mol Biochem Parasitol 1999;102:249-61.
23Burns JM Jr, Shreffler WG, Benson DR, Ghalib HW, Badaro R, Reed SG. Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis. Proc Natl Acad Sci U S A 1993;90:775-9.
24Singh S, Gilman-Sachs A, Chang KP, Reed SG. Diagnostic and prognostic value of K39 recombinant antigen in Indian leishmaniasis. J Parasitol 1995;81:1000-3.
25Singh S, Kumari V, Singh N. Predicting kala-azar disease manifestations in asymptomatic patients with latent Leishmania donovani infection by detection of antibody against recombinant K39 antigen. Clin Diagn Lab Immunol 2002;9:568-72.
26Houghton RL, Petrescu M, Benson DR, Skeiky YA, Scalone A, Badaro R, et al. Cloned antigen (recombinant K39) of Leishmania chagasi diagnostic for visceral leishmaniasis in human immunodeficiency virus type 1 patients and a prognostic indicator for monitoring patients undergoing drug therapy. J Infect Dis 1998;177:1339-44.
27Zijlstra EE, Nur Y, Desjeux P, Khalil EA, El-Hassan AM, Groen J. Diagnosing visceral leishmaniasis with the recombinant K39 strip test: experience from the Sudan. Trop Med Int Health 2001;6:108-13.
28Jensen AT, Goafar A, Ismail A, Christensen CB, Kemp M, Hasan AH, et al. Serodiagnosis of cutaneous leishmaniasis: asseeement of an enzyme linked immunosorbent assay using a peptide sequence from gene B protein. Am J Trop Med Hyg 1996;55:490-5.
29Maalej IA, Chenik M, Louzir H, Ben SA, Bahloul C, Amri F, et al. Comparative evaluation of ELISAs based on ten recombinant or purified Leishmania antigens for the serodiagnosis of mediterrean visceral lesihmaniasis. Am J Trop Med Hyg 2003;68:312-20.
30Brito ME, Mendonca MG, Gomes YM, Jardim ML, Abath FG. Identification of potentially diagnostic Leishmania braziliensis antigens in human cutaneous leishmaniasis by immunoblot analysis. Clin Diagn Lab Immunol 2000;7:318-21.
31Senaldi G, Xiao-su H, Hoessli DC, Bordier C. Serological diagnosis of visceral leishmaniasis by a dot-enzyme immunoassay for the detection of a Leishmania donovani-related circulating antigen.
32J Immunol Methods 2001;193:9-15.
33Attar ZJ, Chance ML, el-Safi S, Carney J, Azazy A, El-Hadi M, et al. Latex agglutination test for the detection of urinary antigens in visceral leishmaniasis. Acta Trop 2001;78:11-6.
34Santos-Gomes G, Gomes-Pereira S, Campino L, Araujo MD, Abranches P. Performance of immunoblotting in diagnosis of visceral Leishmaniasis in human immunodeficiency virus-Leishmania sp-coinfected patients. J Clin Microbiol 2000;38:175-8.
35El Tai NO, El Fari M, Mauricio I, Miles MA, Oskam L, El Safi SH, et al. Leishmania donovani: intraspecific polymorphisms of Sudanese isolates revealed by PCR-based analyses and DNA sequencing. Exp Parasitol 2001;97,35-44.
36Pizzuto M, Piazza M, Senese D, Scalamogna C, Calattini S, Corsico L, et al. Role of PCR in diagnosis and prognosis of visceral leishmaniasis in patients co-infected with human immunodeficiency virus type 1. J Clin Microbiol 2001;39:357-61.
37Wortman G, Sweeney C, Houng H-S, Aronson N, Stiteler J, Jackson J, et al. Rapid diagnosis of Leishmaniasis by fluorogenic polymerase chain reaction. Am J Trop Med Hyg 2001;65:583-7.
38Monroy Ostria, Sanchez-Tezeda G. Molecular probes and the polymerase chain reaction for detection and typing of Leishmania species in Mexico. Trans R Soc Trop Med Hyg 2002;96(Suppl 1):S101-4.
39Chiurillo MA, Sachdeva M, Dole VS, Yepes Y, Miliani E, Vazquez L, et al. Detection of Leishmania causing visceral leishmaniasis in the old and new worlds by a polymerase chain reaction assay based on telomeric sequences. Am J Trop Med Hyg 2001;65:573-62.
40Singh S, McGwire BS, Chang KP. Kinetoplast and nuclear DNA polymorphism of visceral Leishmania isolates from North-eastern India. J Protozool Res 1995;5:27-32.
41Rodriguez N, Guzman B, Rodas A, Takiff H, Bloom BR, Convit J. Diagnosis of cutaneous leishmaniasis and species discrimination of parasites by PCR and hybridization. J Clin Microbiol 1994;32:2246-52.
42Delgado O, Guevara P, Silva S, Belfort E. Follow-up of a human accidental infection by Leishmania (Viannia) braziliensis using conventional immunologic techniques and polymerase chain reaction. Am J Trop Med Hyg 1996;55:267-72.
43Matsumoto T, Hashiguchi Y, Gomez EA, Calvopina MH, Nonaka S, Saya H, et al. Comparison of PCR results using scrape/exudate, syringe-sucked fluid and biopsy samples for diagnosis of cutaneous leishmaniasis in Ecuador. Trans R Soc Trop Med Hyg 1999;93:606-7.
44Mimori T, Matsumoto T, Calvopina MH, Gomez EA, Saya H, Katakura K, et al. Usefulness of sampling with cotton swab for PCR-diagnosis of cutaneous leishmaniasis in the New World. Acta Trop 2002;81:197-202.
45Pinero J, Martinez E, Pacheco R, Aragon Z, De Armas F, Del Castillo A, et al. PCR-ELISA for diagnosis of mucocutaneous leishmaniasis. Acta Trop 1999;73:21-29.
46Paredes R, Laguna F, Clotet B. Leishmaniasis in HIV-infected persons: a review. J Int Assoc Physicians AIDS Care 1997;3:22-39.

Tuesday, November 12, 2019
 Site Map | Home | Contact Us | Feedback | Copyright  and disclaimer